Functional and clinical importance of SGLT2-inhibitors in frailty: from the kidney to the heart
SGLT2 (sodium-glucose cotransporter 2) enables glucose and sodium reabsorption in the
kidney. SGLT2-inhibitors (also known as gliflozins, which include canagliflozin …
kidney. SGLT2-inhibitors (also known as gliflozins, which include canagliflozin …
Dapagliflozin for the treatment of chronic kidney disease
Y Kurata, M Nangaku - Expert Review of Endocrinology & …, 2022 - Taylor & Francis
Introduction Sodium-dependent glucose cotransporter 2 (SGLT2) is a glucose transporter
expressed on the proximal tubular cells, where it reabsorbs glucose from the glomerular …
expressed on the proximal tubular cells, where it reabsorbs glucose from the glomerular …
[HTML][HTML] Neutral effect of SGLT2 inhibitors on lipoprotein metabolism: From clinical evidence to molecular mechanisms
Abstract Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are effective, well-tolerated,
and safe glucose-lowering compounds for patients with type 2 diabetes mellitus (T2DM) …
and safe glucose-lowering compounds for patients with type 2 diabetes mellitus (T2DM) …
Dapagliflozin and anemia in patients with chronic kidney disease
DAPA and Anemia in Patients with CKD This post hoc analysis of the DAPA-CKD
(Dapagliflozin in Patients with Chronic Kidney Disease) trial assessed the impact of …
(Dapagliflozin in Patients with Chronic Kidney Disease) trial assessed the impact of …
Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial
M Schechter, SD Wiviott, I Raz, EL Goodrich… - The Lancet Diabetes & …, 2023 - thelancet.com
Background In people with type 2 diabetes at high risk of cardiovascular or kidney disease,
sodium-glucose co-transporter 2 (SGLT2) inhibitors consistently reduce the risk of …
sodium-glucose co-transporter 2 (SGLT2) inhibitors consistently reduce the risk of …
Potential mediators for treatment effects of novel diabetes medications on cardiovascular and renal outcomes: a meta‐regression analysis
JM Rodriguez‐Valadez, M Tahsin… - Journal of the …, 2024 - Am Heart Assoc
Background Prior research suggests clinical effects of glucagon‐like peptide‐1 receptor
agonists (GLP‐1RAs) and sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) are …
agonists (GLP‐1RAs) and sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) are …
Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in Kidney Disease
JT Ha, S Hiremath, M Jun, SC Green… - NEJM …, 2024 - evidence.nejm.org
Background Hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitors are an oral
treatment for anemia of chronic kidney disease (CKD). In this systematic review and meta …
treatment for anemia of chronic kidney disease (CKD). In this systematic review and meta …
Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Cardiovascular Disease and Chronic Kidney Disease
A Rastogi, JL Januzzi Jr - Journal of Clinical Medicine, 2023 - mdpi.com
Sodium-glucose cotransporter-2 inhibitors (SGLT2is) have been shown to improve
cardiovascular and renal outcomes in patients with established cardiovascular disease …
cardiovascular and renal outcomes in patients with established cardiovascular disease …
Hemochromatosis gene mutation in persons developing erythrocytosis on combined testosterone and sglt-2 inhibitor therapy
KA Schumacher, AR Gosmanov - Journal of Investigative …, 2022 - journals.sagepub.com
In clinical trials, sodium-glucose cotransporter-2 inhibitors (SGLT-2i) use alone in persons
with type 2 diabetes (T2D) or testosterone replacement therapy (TRT) prescription alone in …
with type 2 diabetes (T2D) or testosterone replacement therapy (TRT) prescription alone in …
Efecto de los inhibidores del cotransportador sodio-glucosa tipo 2 sobre la anemia: posibles implicaciones clínicas
Los inhibidores del cotransportador sodio-glucosa tipo 2 (iSGLT2) han demostrado su
beneficio cardiovascular y renal en pacientes con diabetes mellitus tipo 2, insuficiencia …
beneficio cardiovascular y renal en pacientes con diabetes mellitus tipo 2, insuficiencia …